Kamada (NASDAQ:KMDA - Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.02, Zacks reports. The business had revenue of $39.01 million for the quarter, compared to analysts' expectations of $146.55 million. Kamada had a net margin of 9.92% and a return on equity of 6.30%. Kamada updated its FY 2025 guidance to EPS.
Kamada Stock Performance
NASDAQ:KMDA traded up $0.09 during trading hours on Friday, reaching $7.41. The company's stock had a trading volume of 266,599 shares, compared to its average volume of 264,311. The firm has a 50-day simple moving average of $7.13 and a 200-day simple moving average of $6.16. Kamada has a 1 year low of $4.74 and a 1 year high of $9.15. The firm has a market capitalization of $425.93 million, a price-to-earnings ratio of 26.46, a PEG ratio of 0.97 and a beta of 0.97.
Kamada Dividend Announcement
The business also recently declared a dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be issued a $0.20 dividend. The ex-dividend date is Monday, March 17th.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Kamada in a research report on Thursday.
Read Our Latest Report on Kamada
Kamada Company Profile
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Featured Stories
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
